Regeneron Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Leonard S. Schleifer
- Full Time Employees
- 15,410
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States of America 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases including eye disorders, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. Founded in 1988 and headquartered in Tarrytown, New York, the company operates globally with facilities in the United States and clinical trials underway in more than 50 countries; it employs proprietary technologies such as VelociSuite for fully human antibodies and bispecifics, Trap fusion proteins and the Regeneron Genetics Center for data-powered insights. Its marketed products include EYLEA (aflibercept) for retinal diseases such as wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion; Dupixent (dupilumab, in collaboration with Sanofi) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic conditions; Praluent (alirocumab) for hypercholesterolemia; Kevzara (sarilumab, with Sanofi) for rheumatoid arthritis; Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and other cancers; ARCALYST (rilonacept) for autoinflammatory diseases; ZALTRAP (ziv-aflibercept) for metastatic colorectal cancer; Inmazeb for Ebola virus infection; Veopoz (pozelimab) for CHAPLE disease; as well as investigational candidates across oncology, hematology, immunology and neurology. In recent developments, Regeneron formed Regeneron Cell Medicines in 2024 through an agreement acquiring 2seventy bio's immune cell therapy pipeline, discovery and manufacturing capabilities along with approximately 150 employees in Cambridge, Massachusetts, and Seattle, Washington; announced a $3 billion-plus, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies in 2025 to nearly double U.S. large-scale capacity at the Holly Springs, North Carolina facility; launched a $500 million venture capital fund in 2024 focused on biotech investments; entered a collaboration with Tessera Therapeutics in December 2025 to co-develop TSRA-196, a gene-editing therapy for alpha-1 antitrypsin deficiency, with Tessera receiving $150 million upfront and up to $125 million in milestones; secured FDA approval for EYLEA HD in retinal vein occlusion with expanded dosing in 2025; and won a $406.8 million antitrust judgment against Amgen in May 2025 over Praluent market exclusion. The company continues to advance its pipeline with positive late-stage data in immunology, allergy, neurology and rare diseases, while expanding R&D investments and domestic manufacturing to support growth.
Company News
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in Stock
Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More
Longleaf Partners Global Fund Q3 2026 Portfolio Review
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Longleaf Partners Fund Q3 2026 Portfolio Review
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by NorthCrest Asset Manangement LLC
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Central Pacific Bank Trust Division
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026